EOS imaging obtains Innovative Technology status from the Korean National Evidence-Based Healthcare Collaborating Agency


The EOS imaging platform has been granted Innovative Technology Status from the Korean National Evidence-based Healthcare Collaborating Agency (NECA). This categorises EOS as a unique modality, giving it a new reimbursement code with higher coverage than conventional X-rays.

NECA was established under the Korean Ministry of Health and Welfare to look at the safety, effectiveness and cost-effectiveness of relevant technologies, as well as their social, legal and ethical effects. Using a systematic literature review, the agency comprehensively searches and analyses existing studies to evaluate applications.

EOS was granted the Innovative Technology status on the basis of the combination of its dose reduction, simultaneous biplanar scanning and 3D reconstruction capacity, according to a company release.

Now that EOS imaging has received this status, an EOS exam will be registered in the health insurance benefits coverage list as a specific modality. During the coming years, reimbursement levels will be determined. In the meantime, hospitals may determine for themselves the amount they will charge for each exam.

EOS imaging received the Korean Food and Drug Administration (KFDA) clearance in 2014.